ArticleSchizophrenia bulletin2026
The Risk of Very Late-Onset Schizophrenia Following Diabetes Type 2 Onset: A Nationwide Population-Based Study of Midlife and Old-Age.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and hypothesisSchizophrenia is an established Type 2 Diabetes (T2D) risk factor; while the reverse hypothesis is plausible, it remains untested. STUDY
designThis nationwide cohort study included all members (n = 99 567; Female: 52517, 52.7%) of a non-profit Israeli health maintenance organization born between 1932 and 1952. At cohort entry (aged M = 59.70, SD = 5.68) without histories of T2D or schizophrenia, the cohort was followed-up on average 14.47 (SD = 2.28) years for incident schizophrenia. Cox regression models were fit to quantify the association between T2D and schizophrenia risk with the Hazard Ratio (HR) and their 95% Confidence Intervals (CI), unadjusted and adjusted for 20 potential confounders in the primary analysis. STUDY
resultsDuring follow-up, schizophrenia incidence per 10 000 person-years was 0.26 (95% CI, 0.21-0.32) in individuals with T2D and 0.12 (95% CI, 0.11-0.14) in those without. In the primary analysis, T2D onset was associated with a 50% increased risk of incident schizophrenia (adjusted hazard ratio = 1.53; 95% CI, 1.11-2.10; P = .009) compared with the absence of T2D. Generally, nine complementary analyses were consistent with the primary analysis results, showing T2D was associated with an increased risk of incident schizophrenia; the association showed minimal reverse causation and antidiabetic medication was not associated with schizophrenia risk.
conclusionsIn this study, the onset of T2D was associated with an increased risk of schizophrenia. This suggests that the onset of T2D may require psychosis monitoring, which is relevant to healthcare providers and clinicians in psychiatry, geriatrics, and endocrinology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.